The president of the Group of Biotechnological and Pharmaceutical Industries (BioCubaFarma), Eduardo Martínez, declared to the Cubavisión Internacional channel that in the latest case they are working on a product related to macular degeneration, a pathology that causes blindness from the elderly and has few treatment alternatives.
He highlighted the creation of a drug to treat Parkinson’s and cerebral infarctions, jointly by the Center for Drug Research and Development and the University of Havana.
He specified that Jusvinza, for the treatment of rheumatoid arthritis, will soon enter phase III clinical study, and so far has shown high safety and the effects are noticeable in a short period of time.
BioCubaFarma has 14 production and innovation research projects related to cancer, in which other countries are involved, one of the main causes of death worldwide.
“We have been developing for about 10 years a new therapeutic vaccine against cancer with an antiangiogenic effect. We can say with satisfaction that of the 30 patients who participated in the phase I clinical study, who had a life expectancy of around six months, many of them joined the work,” he said.
Regarding the CIGB-Mariel Biotechnological Industrial Complex, the president of the group reported that the first batches of their own Covid-19 vaccines have already been manufactured.
pgh/llp/gas/nmr
